Atea Pharmaceuticals (AVIR) Competitors $3.22 -0.09 (-2.72%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends AVIR vs. INO, MESO, IMTX, SEPN, COLL, PAHC, CRGX, CGEM, ETNB, and RAPPShould you be buying Atea Pharmaceuticals stock or one of its competitors? The main competitors of Atea Pharmaceuticals include Inovio Pharmaceuticals (INO), Mesoblast (MESO), Immatics (IMTX), Septerna (SEPN), Collegium Pharmaceutical (COLL), Phibro Animal Health (PAHC), CARGO Therapeutics (CRGX), Cullinan Therapeutics (CGEM), 89bio (ETNB), and Rapport Therapeutics (RAPP). These companies are all part of the "medical" sector. Atea Pharmaceuticals vs. Inovio Pharmaceuticals Mesoblast Immatics Septerna Collegium Pharmaceutical Phibro Animal Health CARGO Therapeutics Cullinan Therapeutics 89bio Rapport Therapeutics Atea Pharmaceuticals (NASDAQ:AVIR) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability, valuation and community ranking. Which has better earnings and valuation, AVIR or INO? Inovio Pharmaceuticals has lower revenue, but higher earnings than Atea Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtea Pharmaceuticals$351.37M0.77-$135.96M-$2.07-1.56Inovio Pharmaceuticals$591.86K187.10-$135.12MN/AN/A Which has more risk & volatility, AVIR or INO? Atea Pharmaceuticals has a beta of 0.17, indicating that its share price is 83% less volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Is AVIR or INO more profitable? Atea Pharmaceuticals' return on equity of -34.90% beat Inovio Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Atea PharmaceuticalsN/A -34.90% -32.38% Inovio Pharmaceuticals N/A -99.51%-70.90% Does the MarketBeat Community favor AVIR or INO? Inovio Pharmaceuticals received 700 more outperform votes than Atea Pharmaceuticals when rated by MarketBeat users. Likewise, 71.23% of users gave Inovio Pharmaceuticals an outperform vote while only 47.37% of users gave Atea Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAtea PharmaceuticalsOutperform Votes1847.37% Underperform Votes2052.63% Inovio PharmaceuticalsOutperform Votes71871.23% Underperform Votes29028.77% Does the media favor AVIR or INO? In the previous week, Inovio Pharmaceuticals had 12 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 17 mentions for Inovio Pharmaceuticals and 5 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.72 beat Inovio Pharmaceuticals' score of 0.07 indicating that Atea Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inovio Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals have more ownership in AVIR or INO? 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 17.8% of Atea Pharmaceuticals shares are owned by insiders. Comparatively, 2.5% of Inovio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts rate AVIR or INO? Atea Pharmaceuticals presently has a consensus price target of $6.88, suggesting a potential upside of 113.66%. Inovio Pharmaceuticals has a consensus price target of $43.60, suggesting a potential upside of 922.27%. Given Inovio Pharmaceuticals' higher possible upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Atea Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00Inovio Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 SummaryAtea Pharmaceuticals and Inovio Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Ad DTILet’s be bluntLet me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVIR vs. The Competition Export to ExcelMetricAtea PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$271.97M$6.39B$5.07B$8.66BDividend YieldN/A8.08%5.10%4.06%P/E Ratio-1.5610.92101.9217.46Price / Sales0.77245.131,196.9569.07Price / CashN/A53.4941.0436.36Price / Book0.599.306.345.87Net Income-$135.96M$154.14M$119.64M$225.66M7 Day Performance-8.00%-9.47%-5.13%-1.34%1 Month Performance-13.67%-7.30%-2.72%1.15%1 Year Performance6.27%28.21%31.10%24.02% Atea Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVIRAtea Pharmaceuticals3.5142 of 5 stars$3.22-2.7%$6.88+113.7%+10.7%$271.97M$351.37M-1.5670Positive NewsINOInovio Pharmaceuticals3.6459 of 5 stars$5.34-3.6%N/A-92.8%$143.84M$591,858.000.00127Analyst ForecastNews CoverageGap UpMESOMesoblast1.5901 of 5 stars$9.74+6.0%N/A+298.4%$1.11B$5.90M0.0080News CoverageGap DownIMTXImmatics2.3143 of 5 stars$9.04-2.3%N/A-3.9%$1.08B$58.44M-10.16260Short Interest ↓SEPNSepternaN/A$25.46-1.7%N/AN/A$1.07B$838,000.000.00N/APositive NewsCOLLCollegium Pharmaceutical4.1071 of 5 stars$32.18+0.1%N/A+17.8%$1.04B$566.77M13.87210PAHCPhibro Animal Health4.3687 of 5 stars$25.55+7.1%N/A+132.3%$1.03B$1.02B59.421,940Analyst UpgradeHigh Trading VolumeCRGXCARGO Therapeutics1.7566 of 5 stars$21.98-1.7%N/A+8.5%$1.01BN/A-0.43116Earnings ReportAnalyst ForecastNews CoverageCGEMCullinan Therapeutics2.1817 of 5 stars$17.27+7.8%N/A+54.5%$1.00B$18.94M-6.0830Positive NewsHigh Trading VolumeETNB89bio1.7189 of 5 stars$10.05-3.8%N/A+6.3%$988.72MN/A-3.4540Analyst RevisionNews CoverageRAPPRapport Therapeutics1.5547 of 5 stars$26.90+0.8%N/AN/A$983.89MN/A0.00N/ANews Coverage Related Companies and Tools Related Companies Inovio Pharmaceuticals Alternatives Mesoblast Alternatives Immatics Alternatives Septerna Alternatives Collegium Pharmaceutical Alternatives Phibro Animal Health Alternatives CARGO Therapeutics Alternatives Cullinan Therapeutics Alternatives 89bio Alternatives Rapport Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AVIR) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
